Eosinophilic esophagitis (EoE) - Brooklyn NY

Summary:

Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and is characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus.

We are doing this study to learn more about an investigational drug called tezepelumab. We would like to know if it could be an effective and safe treatment for eosinophilic esophagitis (EoE). We also aim to better understand the disease and associated health problems.

In December 2021, tezepelumab was approved by the US Food and Drug Administration (FDA) as a treatment for adults and adolescents with severe asthma. It has also been approved in Switzerland, Canada, Brazil, European Union, the United Kingdom, Japan, and Iceland as of 30 November 2022.

• Are between 12–80 years of age
• Have been diagnosed with EoE
• Have problems with swallowing on a regular basis
• Have been treated for EoE before OR Are currently receiving treatment for EoE

Qualified Participants May Receive:

The Qualified participant will be paid a small stipend to cover the cost of time and travel for study visits. The stipend for each visit is described below

1 Screening: $180

2 Baseline Visit: $180

3 week 4 Visit: $180

4 week 8 Visit: $180

5 week 12 Visit: $180

6 week 16 Visit: $180

7 week 20 Visit: $180

8 week 24 Visit: $180

9 week 28 Visit: $180

10 week 32 Visit: $180

11 week 36 Visit: $180

12 week 40 Visit: $180

13 week 44 Visit: $180

14 week 48 Visit: $180

15 week 52 Visit: $180

You will be paid following each completed visit.